LUND,
Sweden, April 25, 2024 /PRNewswire/ --
First quarter
- Net sales reached SEK 9.4 (13.0)
million.
- The operating result totaled SEK
-18.4 (-14.4) million.
- Earnings per share, basic and diluted, were SEK -0.11 (-0.09).
- Cash flow from operating activities totaled SEK -7.3 (-12.2) million.
CEO Comment
"Sales for the first quarter were lower than the same period
last year, which in its entirety is due to the low partner sales.
In the Swedish market, sales were up by 21% compared to the same
quarter last year, and our market share continues to increase.
During the quarter, ColdZyme was MDR certified as one of the first
cold products in Europe, which
opens up great commercial opportunities. We can make stronger and
better health claims, that will fortify our marketing, and we have
received validation of the high quality of our scientific and
regulatory documentation. I see that 2024 has every chance of being
an important and exciting year for Enzymatica. We have the MDR
certification in place, we are hoping for good research results
during the second quarter, and we are engaged in discussions with
potential partners with great faith in our technology, our product
and our capabilities", said Claus Egstrand, CEO.
Significant events during the quarter
- On February 16, 2024, the Board
of Directors decided to carry out a rights issue, with preferential
rights for existing shareholders, of SEK
27.4 million before issue expenses. The rights issue was
72.7 percent subscribed with the support of subscription rights and
7.9 percent without the support of subscription rights. The
remaining part of the rights issue was subscribed through guarantee
commitments from Enzymatica's three largest owners, through wholly
or partly owned companies, and the Chairman of the Board and CEO.
After issue expenses, the company receives SEK 25.5 million.
- ColdZyme® was certified in March
2024 under the EU MDR (Class III) regulation. The MDR
replaces the EU's Medical Device Directive (MDD) and imposes
stricter requirements on the evidence for clinical validity, safe
design and market surveillance. ColdZyme is one of the first cold
and flu products to be certified under the regulation.
Significant events after the quarter
- No significant events were reported after the quarter.
Other events during and after the quarter
- On March 2, 2024, Professor
Glen Davison presented the first results from his ongoing
clinical trial on ColdZyme at the IOC's 7th World Conference on
Prevention of Injury and Illness in Sport, the premier
international conference on clinical aspects of sports and exercise
medicine.
- The British Journal of Sports Medicine published an abstract
about the ongoing clinical trial on ColdZyme at the University
of Kent. The initial results from the study showed that ColdZyme
significantly reduced the quantity of rhinovirus and symptoms of
sore throat compared with placebo. The final results of the study
are expected in the first half of 2024.
- Enzymatica will participate in the Global Health Campaign
initiative that brings together consumer health and life science
companies. At the end of May 2024,
participating companies will join researchers and experts for the
Global Health Summit in Geneva.
- The Swedish government has tasked the Swedish Agency for Health
Technology Assessment and Assessment of Social Services with the
task of investigating the state of knowledge regarding the effect
of products that are claimed to combat colds. The assignment must
be reported by 1 September 2024 at
the latest.
The full report is available on:
www.enzymatica.com/investors/financial-reports
This information is information that Enzymatica is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out below, at 08:30
a.m. CET on April 25,
2024.
For more information, please contact:
Claus Egstrand,
Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Stefan Olsson, Communication
Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund,
Sweden, and is listed on Nasdaq First North Growth
Market.
For more information, please visit www.enzymatica.se. Enzymatica's
Certified Adviser is Carnegie Investment Bank AB (publ).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/enzymatica-ab/r/interim-report-q1-2024--mdr-certification-opens-up-great-commercial-opportunities,c3967653
The following files are available for download:
https://mb.cision.com/Main/18091/3967653/2759265.pdf
|
The full report
(PDF)
|
https://mb.cision.com/Public/18091/3967653/b2ca5530e5223012.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/enzymatica-interim-report-q12024-mdr-certification-opens-up-great-commercial-opportunities-302127193.html